Current stage?-Stage III - Page 2 of 33 Posts on Medivizor

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Posted by Medivizor on Oct 24, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Posted by Medivizor on Oct 17, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to investigate the safety and effectiveness of immunotherapy drug tebentafusp in previously untreated advanced uveal melanoma. The study showed that tebentafusp is effective and improved the overall survival in patients with uveal melanoma. Some background Melanoma is an aggressive kind of skin cancer. Uveal melanoma...

Apalutamide plus androgen deprivation therapy preserves health-related quality of life in patients with non-metastatic castration-resistant prostate cancer.

Posted by Medivizor on Oct 9, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effects on the health-related quality of life (HR-QoL) of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that apalutamide plus ADT preserved HR-QoL in these patients. Some background...

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Posted by Medivizor on Oct 3, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the use of osimertinib (Tagrisso) for the treatment of EGFR-mutant advanced non-small-cell lung cancer (NSCLC) in a real-world practice. It found that osimertinib was confirmed to improve survival without cancer progressing, while the occurrence of blood clots was more common in a real-world...

Which is the best approach for treating lateral lymph node metastasis in locally advanced rectal cancer?

Posted by Medivizor on Sep 17, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the best approach for treating lateral lymph node (LLNs) metastasis in patients with locally advanced rectal cancer (LARC). The data showed that a radiation dose boost is an effective way of increasing the response rate and decreasing recurrence rates in these patients. Some background Rectal cancer (RC) is one...

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Posted by Medivizor on Sep 12, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the optimal time interval between chemoradiotherapy (CRT) and surgery and its impact on survival outcomes in patients with locally advanced (LA) non-small-cell lung cancer (NSCLC). The data showed that surgery within 7 weeks after CRT was associated with improved survival outcomes in these patients. Some...

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Posted by Medivizor on Sep 5, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of triple combination therapy with immune and targeted therapies in patients with stage III-IV melanoma. The data showed that triple combination therapy was associated with increased survival benefits with manageable side effects for these patients. Some background Melanoma is an...

Evaluating the benefits of denosumab on bone health in women with early-stage breast cancer.

Posted by Medivizor on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the benefits of denosumab (Xgeva) on the bone health of women with early-stage breast cancer (BC). The data showed that denosumab improved bone-related outcomes in women with high-risk early-stage BC Some background BC is one of the most common forms of cancer in women. Early-stage BC is used to describe BC that is...

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Posted by Medivizor on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the role of 18F-fluciclovine-PET-CT versus conventional imaging (bone scan and either CT or MRI) alone for salvage radiotherapy (RT) after prostate surgery for the treatment of patients with localized prostate cancer (PCa). The data showed that including 18F-fluciclovine-PET-CT into the decision-making process for RT...

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by Medivizor on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Evaluating outcomes of laparoscopic surgery for the treatment of elderly patients over 80 years with colorectal cancer.

Posted by Medivizor on Jul 31, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the short- and long-term outcomes of laparoscopic surgery (LS; keyhole surgery) for the treatment of elderly patients with colorectal cancer (CRC) aged over 80 years. The data showed that LS is a good and safe option for these patients. Some background Colorectal cancer (CRC) is one of the most common types of cancer...

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Posted by Medivizor on Jul 24, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...

Current stage?-Stage III Posts on Medivizor

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Apalutamide plus androgen deprivation therapy preserves health-related quality of life in patients with non-metastatic castration-resistant prostate cancer.

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Which is the best approach for treating lateral lymph node metastasis in locally advanced rectal cancer?

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Evaluating the benefits of denosumab on bone health in women with early-stage breast cancer.

Should 18F-fluciclovine-PET/CT be included into the decision-making process for radiotherapy after surgery for prostate cancer?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Evaluating outcomes of laparoscopic surgery for the treatment of elderly patients over 80 years with colorectal cancer.

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Categories

Recent Posts

Archives

Current stage?-Stage III Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email